APA

Kinugasa H., Ikeda F., Takaguchi K., Mori C., Matsubara T., Shiraha H., Takaki A., Iwasaki Y., Toyooka S. & Yamamoto K. (20161213). Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. : Antiviral therapy.

Chicago

Kinugasa Hideaki, Ikeda Fusao, Takaguchi Kouichi, Mori Chizuru, Matsubara Takehiro, Shiraha Hidenori, Takaki Akinobu, Iwasaki Yoshiaki, Toyooka Shinichi and Yamamoto Kazuhide. 20161213. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. : Antiviral therapy.

Harvard

Kinugasa H., Ikeda F., Takaguchi K., Mori C., Matsubara T., Shiraha H., Takaki A., Iwasaki Y., Toyooka S. and Yamamoto K. (20161213). Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. : Antiviral therapy.

MLA

Kinugasa Hideaki, Ikeda Fusao, Takaguchi Kouichi, Mori Chizuru, Matsubara Takehiro, Shiraha Hidenori, Takaki Akinobu, Iwasaki Yoshiaki, Toyooka Shinichi and Yamamoto Kazuhide. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. : Antiviral therapy. 20161213.